Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
NCT03717181 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-10-14
Summary
Abdominal pain, sometimes severe, is a known symptom of polycystic kidney disease (PKD) related to the cystic expansion. This study will investigate whether the vasopressin V2 receptor antagonist lixivaptan can alleviate intractable pain in a pediatric PKD patient who cannot tolerate the related vasopressin V2 receptor antagonist tolvaptan.
Conditions
- Polycystic Kidney
Interventions
- DRUG
-
Lixivaptan
Daily dose of lixivaptan optimized using a predetermined titration protocol.
Sponsors & Collaborators
-
Palladio Biosciences
lead INDUSTRY
Principal Investigators
-
Marie C Hogan, MD, PhD · Mayo Clinic
Eligibility
- Min Age
- 15 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01500798 ·Status: TERMINATED ·Phase: PHASE1
-
Prospective Decision Impact Trial of KidneyIntelX
NCT04960514 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
NCT03949894 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
NCT06391450 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
NCT01377935 ·Status: COMPLETED
-
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NCT02010242 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05719714 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
NCT06489340 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945 ·Status: RECRUITING ·Phase: PHASE3
-
Study of LY3016859 in Participants With Diabetic Nephropathy
NCT01774981 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
NCT05198284 ·Status: ACTIVE_NOT_RECRUITING
-
Pentoxifylline in Diabetic Kidney Disease
NCT03625648 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
NCT05182840 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
NCT00663949 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
NCT05715814 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
NCT01712061 ·Status: COMPLETED ·Phase: PHASE2
-
Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data
NCT04882813 ·Status: COMPLETED
-
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
NCT07012005 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
NCT02289703 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of LIXIsenatide on the Renal System
NCT02276196 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
NCT01200394 ·Status: COMPLETED ·Phase: PHASE2
-
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
NCT00312780 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
NCT07271186 ·Status: RECRUITING ·Phase: PHASE2
-
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
NCT05373004 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
NCT03471117 ·Status: RECRUITING ·Phase: PHASE4